Drug intelligence / Profile preview

GammFlu-COVID

Development stage: Preclinical
Lead developer: Gamma Vaccines
Modality: Vaccines & Immunotherapeutics

Overview

**GammFlu-COVID** is a preclinical combination vaccine being developed by Gamma Vaccines for prevention of **COVID-19** and **influenza**. It combines the company's proprietary **GammaFlu** whole inactivated influenza vaccine with a COVID-19 vaccine component. The influenza component is produced using Gamma Vaccines' gamma-irradiation photon inactivation platform, which is intended to preserve native viral antigenic structure better than chemical inactivation and thereby induce both humoral antibody and T-cell mediated immune responses. The program is positioned as a dual-pathogen prophylactic vaccine, with the GammaFlu component also described as having adjuvant-like activity that may enhance the co-administered COVID vaccine response.

Other names: GammFlu-COVIDGammaFlu-COVID

Beyond the preview

Go deeper on GammFlu-COVID.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GammFlu-COVID.

Explore the full profile